Erlonat

 Introduction

Erlonat 150 Tablet is used to treat non-small cell lung cancer and pancreatic cancer.

Erlonat 150 tablets should be taken on an empty stomach, one hour before or two hours after a meal. You should continue taking it as long as your doctor recommends it. The duration of treatment varies according to your needs and response to treatment. You should take it exactly as recommended by your doctor. Taking the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel these benefits, but unless your doctor tells you, do not stop taking it.


The most common side effects of this drug include nausea, vomiting, fatigue, skin rash and weight loss. It may cause severe diarrhea, drink plenty of water or trouble your doctor. It makes you sensitive to sunlight, so wear protective clothing or use sunscreen when you go out. If you have mouth ulcers, vision changes or difficulty breathing, it is best to notify your doctor. While you are taking this medicine, your doctor may recommend that you regularly monitor liver function.

Many other medicines may affect or be affected by this medicine, so please let your medical team know about all medicines you are taking. This medication is not recommended during pregnancy or breastfeeding. During treatment, both men and women should use effective contraceptive methods, which is important to avoid pregnancy. It is recommended that you quit smoking while taking this drug because it will affect the efficacy of the drug. If you must take antacids or any other medicines, please take them within at least 2 hours after taking the anticancer medicine.

USES OF ERLONAT TABLET

Non-small cell lung cancer

Pancreatic cancer

Benefits of ERLONAT tablets

Non-small cell lung cancer

Non-small cell lung cancer is one of the main types of lung cancer. It affects both smokers and non-smokers. Erlonat 150 tablets help treat non-small cell lung cancer and can be used alone or in combination with other drugs. This is an effective and highly toxic drug, and you should discuss the risks and benefits with your doctor. During this treatment, you should avoid drinking alcohol and drink plenty of water to stay hydrated.

SIDE EFFECTS OF ERLONAT TABLET

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Erlonat

Abdominal pain

Bone pain

Breathlessness

Constipation

Cough

Diarrhea

Fatigue

Fever

Infection

Muscle pain

Nausea

Rash

Stomatitis (Inflammation of the mouth)

Vomiting

Weight loss

How to use ERLONAT tablet

Take this medicine according to the dosage and duration recommended by your doctor. Swallow whole. Do not chew, crush or break it. Erlonat 150 tablets should be taken on an empty stomach.

How the ERLONAT tablet works

Erlonat 150 Tablet is an anti-cancer drug. Epidermal growth factor receptor (EGFR) is expressed on the surface of lung cancer cells that regulate their growth. The drug works by binding to the chemical messenger EGFR, thus inhibiting the EGFR-mediated cancer signaling pathway. This is how it limits the further growth of cancer cells.

Quick tips

Erlonat 150 Tablet can help treat non-small cell lung cancer that is locally advanced or has spread to other parts of the body.

It should be taken 1 hour before meals or 2 hours after meals.

Diarrhea may be a side effect. Drink a lot of fluids. If you don’t stop or if you find blood in your stool, please inform your doctor.

Please use reliable contraceptive methods to prevent pregnancy while taking this drug and one month after stopping taking it.

It makes your skin sensitive to sunlight. Wear sunscreen or protective clothing when you go out.

It is recommended to avoid smoking while taking this drug, as this will make the drug ineffective and require adjustment of the dose.

Do not take it with medicines that lower stomach acid (such as antacids, H2 receptor blockers (including ranitidine)), because it may affect the effectiveness of the medicine.

If you develop mouth ulcers, vision changes or increased coughing, shortness of breath or difficulty breathing while taking this medicine, please tell your doctor.

When you are treated with this medicine, your doctor may want you to have regular blood tests to monitor liver function.

Do not take this medicine if you are pregnant, planning to become pregnant or breastfeeding.

Comments

Post a Comment

Popular posts from this blog

Best Pharma Consulting Company

Image
 Drug Name Atriance 5 mg/ml infusion solution 2. Qualitative and quantitative composition Each milliliter of solution contains 5 mg of Nelarabine. Each vial contains 250 mg of Nelarabine. Excipients with known effects Each milliliter of solution contains 1.770 mg (77 micromoles) of sodium. For a complete list of excipients, see section 6.1. 3. Drug form Infusion solution. Clear colorless solution. 4. Clinical details 4.1 Treatment indications Nelarabine is suitable for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) who have not responded or relapsed after treatment with at least two chemotherapy regimens. Because the number of patients in these conditions is small, the information supporting these indications is based on limited data. 4.2 Modes and methods of administration Nelarabine can only be administered under the guidance of a doctor who has experience in the use of cytotoxic agents. Ontology The complete b...
Read more

Best Pharma Consulting Company

Image
  Indications Instruct VENCLEXTA: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Combine with azacitidine, decitabine or low-dose cytarabine for the treatment of newly diagnosed adult acute myeloid leukemia (AML): 75 years or older, or Patients with comorbidities cannot use intensive induction chemotherapy. Important safety information Contraindications In patients with CLL/SLL, simultaneous use of VENCLEXTA with strong CYP3A inhibitors is contraindicated because it may increase the risk of tumor lysis syndrome (TLS). Tumor lysis syndrome Patients treated with VENCLEXTA developed tumor lysis syndromes, including fatal events and renal failure requiring dialysis. VENCLEXTA can cause rapid tumor reduction, so in all CLL/SLL patients, there is a risk of TLS during the start and the start phase, and during the restart period after the dose is interrupted. Changes in blood chemistry consistent with TLS need to be dealt wi...
Read more

Best Pharma Consulting Company

Image
  About Veenat 400 mg tablets 10 Veenat 400 mg tablets belong to a class of drugs called "anti-cancer drugs" and are mainly used to treat various types of cancer. It is used to treat blood cancers (chronic myeloid leukemia and acute lymphocytic leukemia) and gastrointestinal stromal tumors. Cancer is a genetic change in which our cells divide uncontrollably and spread into surrounding tissues. There are more than 100 kinds of cancer, including blood cancer, lung cancer, breast cancer and so on. 10 Veenat 400 mg tablets contain imatinib, which is mainly used to treat cancer. It works by inhibiting the enzymes responsible for the proliferation of cancer cells and induces cell death (apoptosis). As a result, the growth and spread of cancer cells stopped or slowed down. Take 10 Veenat 400 mg tablets as prescribed by your doctor. It is recommended that you take 10 Veenat 400 mg tablets according to your doctor's condition, as long as your doctor has prescribed it for you. In s...
Read more